Robert Driscoll
Stock Analyst at Wedbush
(2.13)
# 2,943
Out of 5,005 analysts
148
Total ratings
34.62%
Success rate
-2.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $73 → $77 | $46.71 | +64.85% | 6 | Sep 11, 2025 | |
| REPL Replimune Group | Downgrades: Neutral | $19 → $4 | $4.73 | -15.43% | 6 | Jul 22, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $11.72 | +130.38% | 1 | Jul 14, 2025 | |
| KURA Kura Oncology | Reiterates: Outperform | $36 | $9.57 | +276.18% | 10 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.61 | +148.45% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $2.05 | +192.68% | 3 | May 9, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $7.74 | +119.64% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $9.61 | +24.87% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $7.95 | +302.52% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $27.64 | +88.13% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $13.66 | +104.98% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.89 | +311.31% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $13.35 | +124.72% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $14.83 | +243.90% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.83 | +499.16% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $5.90 | +510.17% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.50 | +633.33% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.64 | +180.17% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $7.76 | +67.53% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $24.00 | +208.33% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.70 | +116.22% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.35 | +418.52% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $3.30 | +142.42% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.38 | -8.68% | 4 | May 19, 2020 |
Revolution Medicines
Sep 11, 2025
Maintains: Outperform
Price Target: $73 → $77
Current: $46.71
Upside: +64.85%
Replimune Group
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $4
Current: $4.73
Upside: -15.43%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $11.72
Upside: +130.38%
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $9.57
Upside: +276.18%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.61
Upside: +148.45%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $2.05
Upside: +192.68%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $7.74
Upside: +119.64%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $9.61
Upside: +24.87%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $7.95
Upside: +302.52%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $27.64
Upside: +88.13%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $13.66
Upside: +104.98%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.89
Upside: +311.31%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $13.35
Upside: +124.72%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $14.83
Upside: +243.90%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.83
Upside: +499.16%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $5.90
Upside: +510.17%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.50
Upside: +633.33%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.64
Upside: +180.17%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $7.76
Upside: +67.53%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $24.00
Upside: +208.33%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $3.70
Upside: +116.22%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.35
Upside: +418.52%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $3.30
Upside: +142.42%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.38
Upside: -8.68%